Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Microbix to JV with Hunan Biopharma on $200 Million Flu Facility

publication date: Nov 2, 2009

Microbix has signed a joint venture agreement with the Hunan Biopharmaceutical Co. Ltd., a state-owned enterprise, to construct a very large, $200 million facility dedicated to influenza vaccine production. The facility will be Asia's largest flu plant and the third largest vaccine facility in the world. Microbix and Hunan Biopharma will each own 50% of the JV. Microbix originally announced plans for the JV well over a year ago.  More details...

Stock Symbol: (TSX: MBX)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here